Skip to main content
. 2023 Oct 25;14:1285374. doi: 10.3389/fphar.2023.1285374

FIGURE 3.

FIGURE 3

A schematic illustration of acquired resistance mechanisms to ALK inhibitors, including (A) resistance mutations; (B) amplification; (C) bypass signaling; (D) epithelial to mesenchymal transition. (E) A potential course of sequential treatment of ALK-positive cancer with a development of subsequent resistance mutations.